Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.32−0.08 (-1.48%)
Close on Nov 18, 2026Market cap $407.08MP/E –Yield –
Candel Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Candel Therapeutics's total assets was $208.15M at Jun 30, 2026. For fiscal 2025 it was $125.20M, up 17.2% from the year before. The highest annual figure on record is $125.20M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.20M | +17.2% |
| FY2024 | Dec 31, 2024 | $106.87M | +159.4% |
| FY2023 | Dec 31, 2023 | $41.20M | -47.0% |
| FY2022 | Dec 31, 2022 | $77.69M | -12.9% |
| FY2021 | Dec 31, 2021 | $89.21M | +133.0% |
| FY2020 | Dec 31, 2020 | $38.28M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $208.15M | +96.4% |
| Q1 FY2026 | Mar 31, 2026 | $201.92M | +110.5% |
| Q4 FY2025 | Dec 31, 2025 | $125.20M | +17.2% |
| Q3 FY2025 | Sep 30, 2025 | $93.60M | +335.0% |
| Q2 FY2025 | Jun 30, 2025 | $105.97M | +300.1% |
| Q1 FY2025 | Mar 31, 2025 | $95.91M | +207.2% |
| Q4 FY2024 | Dec 31, 2024 | $106.87M | +159.4% |
| Q3 FY2024 | Sep 30, 2024 | $21.52M | -57.0% |
| Q2 FY2024 | Jun 30, 2024 | $26.49M | -54.9% |
| Q1 FY2024 | Mar 31, 2024 | $31.22M | -53.6% |
| Q4 FY2023 | Dec 31, 2023 | $41.20M | -47.0% |
| Q3 FY2023 | Sep 30, 2023 | $50.06M | -41.1% |
| Q2 FY2023 | Jun 30, 2023 | $58.71M | -37.1% |
| Q1 FY2023 | Mar 31, 2023 | $67.24M | -33.8% |
| Q4 FY2022 | Dec 31, 2022 | $77.69M | -12.9% |
| Q3 FY2022 | Sep 30, 2022 | $85.01M | -11.4% |
| Q2 FY2022 | Jun 30, 2022 | $93.30M | +203.5% |
| Q1 FY2022 | Mar 31, 2022 | $101.56M | +165.3% |
| Q4 FY2021 | Dec 31, 2021 | $89.21M | – |
| Q3 FY2021 | Sep 30, 2021 | $95.96M | – |
| Q2 FY2021 | Jun 30, 2021 | $30.74M | – |
| Q4 FY2020 | Dec 31, 2020 | $38.28M | – |
See a number that looks wrong?